Emergent BioSolutions to Participate in Investor Conferences
Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s senior management team will participate in the following investor...
Emergent BioSolutions to Resume Manufacturing Covid-19 Vaccine at Bayview Facility
Emergent BioSolutions Inc. (NYSE:EBS) announced today that the U.S. Food and Drug Administration (FDA) is allowing Emergent’s Bayview manufacturing facility to resume production of Johnson &...
Emergent BioSolutions Reports Financial Results For Second Quarter 2021
Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the second quarter ended June 30,...
Reverse the Silence Campaign Casts a National Spotlight on Overdose Risks Associated with Opioid Use
An alliance of national nonprofit organizations comprised of Community Anti-Drug Coalitions of America (CADCA), Mothers Against Prescription Drug Abuse (MAPDA), SAFE Project, and Shatterproof,...
Emergent BioSolutions to Release Second Quarter 2021 Financial Results and Conduct a Conference Call on July 29, 2021
Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, July 29, 2021 at 5:00 pm eastern time to discuss the financial results for the second quarter of 2021, recent business...
COVID-19 Vaccine Drug Substance Manufactured by Emergent BioSolutions Authorized as Part of Johnson & Johnson’s Emergency Use Authorization
Emergent continues to work with the FDA to address identified observations at Bayview facility in order to release additional batches and resume production GAITHERSBURG, Md., June 11, 2021 (GLOBE...
Emergent BioSolutions Announces Positive Two-Year Persistence Data From Phase 2 Study Evaluating CHIKV VLP, the Company’s Chikungunya Virus Virus-Like Particle Vaccine Candidate
A dose-related increase in immune response, as measured by anti-chikungunya virus serum neutralizing antibodies (SNA), was previously observed. Two years post-vaccination, SNA mean titers were 19...
Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 20, 2021 at 9:00am EDT
Emergent BioSolutions Inc. (NYSE: EBS) announced today that its 2021 Annual Meeting of Stockholders will be held in a virtual-only format via live audio webcast on Thursday, May 20, 2021 at 9:00 AM...
Emergent BioSolutions to Participate in Investor Conferences
Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s senior management team will participate in the following investor...
Emergent BioSolutions Reports Financial Results for First Quarter 2021
Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the quarter ended March 31,...
Statement on Issuance of Form FDA 483 at Emergent Bayview Facility
he U.S. Food and Drug Administration (FDA) has completed its inspection of Emergent BioSolutions’ (NYSE:EBS) Baltimore-Bayview facility and provided specific feedback. Given the heightened focus on...
Emergent BioSolutions to Release First Quarter 2021 Financial Results and Conduct a Conference Call on April 29, 2021
Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, April 29, 2021 at 5:00 pm eastern time to discuss the financial results for the first quarter of 2021, recent business...